Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Boeree

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
The Journal of Antimicrobial Chemotherapy|October 8, 2024
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial diseaseRalf Stemkens, Arthur Lemson, Simon E Koele, et al.
Chest|August 15, 2021
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary DiseaseRabi Danho, Jodie A Schildkraut, Sanne M H Zweijpfenning, et al.
Plos One|May 16, 2013
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in TanzaniaStellah G Mpagama, Scott K Heysell, Nora D Ndusilo, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2012
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatmentJakko van Ingen, Eric F Egelund, Adrah Levin, et al.
AIDS (London, England)|May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsHanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 2019
Protein binding of rifampicin is not saturated when using high-dose rifampicinCarlijn H C Litjens, Rob E Aarnoutse, Eleonora W J van Ewijk-Beneken Kolmer, et al.
The European Respiratory Journal|April 9, 2019
Nontuberculous mycobacterial pulmonary disease and <i>Aspergillus</i> co-infection: Bonnie and Clyde?Kim Geurts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
BMC Medicine|March 24, 2016
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Patrick P J Phillips, Kelly E Dooley, Stephen H Gillespie, et al.
Emerging Infectious Diseases|January 1, 2009
Invasive disease caused by nontuberculous mycobacteria, TanzaniaJohn A Crump, Jakko van Ingen, Anne B Morrissey, et al.
AIDS (London, England)|July 20, 2002
Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survivalStephen B Gordon, Mas Chaponda, Amanda L Walsh, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|October 8, 2024
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial diseaseRalf Stemkens, Arthur Lemson, Simon E Koele, et al.
Chest|August 15, 2021
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary DiseaseRabi Danho, Jodie A Schildkraut, Sanne M H Zweijpfenning, et al.
Plos One|May 16, 2013
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in TanzaniaStellah G Mpagama, Scott K Heysell, Nora D Ndusilo, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2012
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatmentJakko van Ingen, Eric F Egelund, Adrah Levin, et al.
AIDS (London, England)|May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsHanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 2019
Protein binding of rifampicin is not saturated when using high-dose rifampicinCarlijn H C Litjens, Rob E Aarnoutse, Eleonora W J van Ewijk-Beneken Kolmer, et al.
The European Respiratory Journal|April 9, 2019
Nontuberculous mycobacterial pulmonary disease and <i>Aspergillus</i> co-infection: Bonnie and Clyde?Kim Geurts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
BMC Medicine|March 24, 2016
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Patrick P J Phillips, Kelly E Dooley, Stephen H Gillespie, et al.
Emerging Infectious Diseases|January 1, 2009
Invasive disease caused by nontuberculous mycobacteria, TanzaniaJohn A Crump, Jakko van Ingen, Anne B Morrissey, et al.
AIDS (London, England)|July 20, 2002
Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survivalStephen B Gordon, Mas Chaponda, Amanda L Walsh, et al.
Pageof 13